See more
How many patient advocacy organizations does Genentech have?
Today, Genentech has relationships with more than 400 patient advocacy organizations across 50 disease areas. We work with organizations on public policy, public relations, disease awareness, and collaborations that advance patient communities’ and Genentech’s goals. We are committed to transforming society through meaningful partnerships in our communities that focus on advancing inclusive research and health equity in underserved patient communities.
What is Genentech's mission?
Genentech strives to improve the health and wellbeing of all patients, and to create a future of science that is more diverse, inclusive and equitable. Our giving reflects this vision, and supports schools, community-based organizations, patient groups, and scientific and medical communities to help uncover and deliver solutions that ensure a healthier future for everyone. We’re addressing systemic inequities in our society through partnerships with a wide range of organizations that focus on the issues facing our communities.
Why is patient advocacy important?
They play a vital role in helping people with serious diseases navigate the challenges they face and find a sense of community. They provide manufacturers a window into patients’ experiences so that we better understand their perspectives and needs as we strive to make an impact beyond our medicines by uncovering and pursuing ways to bring potential new treatments to patients.
When did Genentech start patient advocacy?
Genentech’s first step into the patient advocacy space was in 1994 , when we played a pivotal role in helping women with HER2-positive breast cancer get the treatment they needed. More than 25 years later, Genentech continues to lead the industry in engaging with patient communities to better serve our patients and help improve health outcomes. Our commitment to fostering sustainable relationships with advocacy organizations, patients, and their care partners helps Genentech support the patients we serve holistically. We're more than just the medicine.
What is Genentech's patient perspective?
At Genentech, we value the patient perspective and believe the patient voice must be heard – and integrated – as we develop and commercialize our medicines. We look to our patient communities for valuable insights and to help us deepen our understanding of their day-to-day realities, their medical care, and what they desire from a new therapy.
What is the patient perspective?
Patient Perspective. Science can reveal much about an illness, but it can’t tell us how people actually experience their disease. More and more, patients have become experts in their disease and treatment options as well as advocates for their own health, managing critical decisions and choices.
How does the rich exchange of shared information help us?
The rich exchange of shared information has helped us design more patient-friendly protocols and recruit participants in studies. Insights gained from our advocacy partners have enabled us to communicate in ways that reach patients of all cultural backgrounds and to explore ways to increase diversity and minority representation in clinical research by prioritizing health equity in clinical trials.
What is Genentech focused on?from gene.com
Genentech has always focused on developing breakthrough medicines for serious illnesses. We believe every person should get the Genentech medicine they need, and we offer programs to help make this happen.
How much did Genentech pay for patent litigation?from en.wikipedia.org
In November 1999, Genentech agreed to pay the University of California, San Francisco $200 million to settle a nine-year-old patent dispute. In 1990, UCSF sued Genentech for $400 million in compensation for alleged theft of technology developed at the university and covered by a 1982 patent.
What documentary was Genentech in?from en.wikipedia.org
Genentech was featured in the documentary film Something Ventured which premiered in 2011.
What is Tecentriq used for?from en.wikipedia.org
2016: Tecentriq (atezolizumab): First-in-class anti-PD-L1 antibody for the treatment of advanced bladder cancer or metastatic non-small cell lung cancer (NSCLC), both after failure of platinum-based chemotherapy. Tecentriq was granted accelerated approval for its advanced bladder cancer indication due to promising phase II results.
When did Genentech join Roche?from gene.com
Genentech became a member of the Roche Group in March of 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States.
How much money did the University of California General Fund give to the inventors?from en.wikipedia.org
The settlement was to be divided as follows: $30 million to the University of California General Fund, $85 million to the three inventors and two collaborating scientists, $50 million towards a new teaching and research campus for UCSF, and $35 million to support university-wide research.
Is Genentech a top employer?from en.wikipedia.org
The company participates in various policy and civic leadership groups, such as TechNet, and sponsors independent third-party research and publications, such as the journal Nature. Genentech was named Top Employer by Science Magazine on October 7, 2010, where it has been recognized for nine consecutive years.
Renata is one of the most impressive women I have had the pleasure of knowing. Any company would be fortunate to employ her
Say Hello to our new Patient Liaison Manager. Renata Tate is part of Cycle Pharmaceuticals on the US Medical Team and will work closely with…
Clinical Nurse Educator
TEVA NEUROSCIENCE, Charleston, SC October 2012 to July 2019 Clinical Nurse Educator, January 2017 – July 29th Territory SC and part of GA. Supported four products, Copaxone, Austedo, Ajovy, and Cinqair (MS, Severe Asthma, HD and Severe Migraine).
Executive Neurology Sales Specialist
Executive Sales Specialist: Developed territory action plans for top neurologists in Atlanta. Planned and conducted Peer to Peer meetings with key customers in mind. Maintained budget with focus on key neurologists offices. Developed a routing to ensure that targeted neurologists and staff were seen on a regular basis.
Clinical Nurse Educator
INVENTIV COMMERCIAL SERVICE INC., Atlanta, GA March 2010 – October 2012 Clinical Nurse Educator, September 2010 – October 2012 Conducted total office call on key neurology practices to educate HCP and staff. Provided training on Biogen’s patient services in key neurology offices.
Clinical Nurse Educator
Clinical Nurse Educator – Female Sexual Dysfunction, March 2010 – July 2010 Conducted total office call on top gynecologists and family practice doctors in area. Mentored Per Diem nursing team.
Business Manager
Primary Care Business Manager, September 2007 – January 2009 Coached, educated and motivated a 12 member Primary Care Sales Team. Oversaw regional budget ensured best use of resources. Maintained highest and best use for territory budget. Provided oversight to ensure that all company policies were adhered to.
Health Science Liaison
Acted as a medical liaison between Merck and key thought leaders. Conducted ongoing scientific discussions with physicians at academic institutions. Integrated with sales and marketing team to effectively leverage national speakers in Georgia and South Carolina. Arraged for Visiting Professorships at major academic institutions.